secwatch.observer — SEC 8-K summary
======================================

Issuer:     GILEAD SCIENCES, INC. (GILD)
CIK:        0000882095
Form:       8-K
Filed at:   2025-04-24T23:59:59+00:00
Accession:  0000882095-25-000009
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Gilead Q1 revenue flat at $6.7B; GAAP EPS $1.04 vs -$3.34; cuts GAAP EPS guidance
--------------------------------------------------------------------------------

- Total revenue $6.7B unchanged YoY; product sales ex-Veklury up 4% to $6.3B.
- GAAP diluted EPS $1.04 vs $(3.34) in Q1 2024; non-GAAP diluted EPS $1.81 vs $(1.32).
- Biktarvy sales $3.1B (+7% YoY); HIV product sales up 6% to $4.6B.
- Full-year GAAP diluted EPS guidance cut to $5.65-$6.05 from $5.95-$6.35; product sales unchanged.
- Cash $7.9B; operating cash flow $1.8B; $1.0B dividends, $730M buyback in Q1.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/882095/000088209525000009/0000882095-25-000009-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/882095/000088209525000009/gild-20250424.htm
  HTML page:      https://secwatch.observer/filing/0000882095-25-000009

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer